1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” COVID-19 vaccines have been linked to an increase in hair loss conditions.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
1 citations
,
May 2023 in “The Journal of Immunology” CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
1 citations
,
February 2022 in “Experimental Dermatology” Certain proteins are found at higher levels in balding areas compared to non-balding areas, suggesting a link to hair loss. This could be useful for diagnosing and treating hair loss.
1 citations
,
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Fetal skin has unique immune cells different from adult skin.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
1 citations
,
January 2014 in “Hair therapy & transplantation” The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.
1 citations
,
January 2005 in “Experimental Dermatology” MC-1R in skin cells may influence inflammation and collagen production.
1 citations
,
September 2004 in “Experimental Dermatology” MC-1R is present in skin cells and may help reduce inflammation.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
November 2025 in “The Journal of Immunology” BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
September 2025 in “Figshare” Alopecia areata involves complex immune responses, suggesting broader treatments could help.
September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.
July 2025 in “Preprints.org” Specific miRNA profiles can help diagnose and treat alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.
July 2025 in “Journal of Investigative Dermatology” Discoid lupus erythematosus involves immune activation and fibrosis around hair follicles, with shared pathways across humans, dogs, and mice, suggesting potential treatments for both humans and animals.
June 2025 in “Academic Medical Journal” Restoring hair follicle immune privilege may help treat alopecia areata.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
May 2025 in “Nonlinear Analysis Real World Applications” Reducing CD8+ T cell growth can stabilize alopecia areata.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
Certain immune markers and vitamin levels could help diagnose alopecia areata.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.